CN110799218A - 包含sting激动剂的抗体缀合物 - Google Patents

包含sting激动剂的抗体缀合物 Download PDF

Info

Publication number
CN110799218A
CN110799218A CN201880043438.4A CN201880043438A CN110799218A CN 110799218 A CN110799218 A CN 110799218A CN 201880043438 A CN201880043438 A CN 201880043438A CN 110799218 A CN110799218 A CN 110799218A
Authority
CN
China
Prior art keywords
alkyl
alkynyl
alkenyl
radical
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880043438.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·W·小杜本斯基
J·R·布鲁姆
S·坎汉
C·Y·周
K·高蒂尔
L·H·格利克曼
郝学士
D·凯恩
S·卡斯布哈特拉
G·E·卡蒂巴
T·N·L·勒
J·莱昂
J·麦肯纳
S·麦克沃特
C·O·恩杜巴库
W·欧
L·宋
G·S·特里亚
宇野哲郎
T·Y-H·吴
万咏勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Chinook Therapeutics Inc
Original Assignee
Novartis AG
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Aduro Biotech Inc filed Critical Novartis AG
Publication of CN110799218A publication Critical patent/CN110799218A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880043438.4A 2017-04-28 2018-04-26 包含sting激动剂的抗体缀合物 Pending CN110799218A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28
US62/491,879 2017-04-28
PCT/US2018/029570 WO2018200812A1 (en) 2017-04-28 2018-04-26 Antibody conjugates comprising sting agonist

Publications (1)

Publication Number Publication Date
CN110799218A true CN110799218A (zh) 2020-02-14

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043438.4A Pending CN110799218A (zh) 2017-04-28 2018-04-26 包含sting激动剂的抗体缀合物

Country Status (5)

Country Link
EP (1) EP3615080A1 (ja)
JP (1) JP2020517700A (ja)
CN (1) CN110799218A (ja)
AR (1) AR113224A1 (ja)
WO (1) WO2018200812A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592570A (zh) * 2020-05-15 2020-08-28 清华大学 新型sting激动剂及其制备方法和应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CA3082351A1 (en) 2017-11-10 2019-05-16 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210015937A (ko) * 2018-06-01 2021-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 방광암을 치료하기 위한 방법
WO2020014127A1 (en) * 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020092617A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
EP3898697A2 (en) * 2018-12-21 2021-10-27 Novartis AG Antibodies to pmel17 and conjugates thereof
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CA3137119A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
TW202108177A (zh) 2019-05-10 2021-03-01 日商武田藥品工業股份有限公司 抗體藥物結合物
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3147890A1 (en) 2019-07-19 2021-01-28 Immunesensor Therapeutics, Inc. Antibody-sting agonist conjugates and their use in immunotherapy
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
AU2020333990B2 (en) * 2019-08-21 2024-05-23 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
KR20220120586A (ko) * 2019-12-23 2022-08-30 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린 기반의 항체-약물 컨쥬게이트의 생성 방법
WO2021177438A1 (ja) * 2020-03-06 2021-09-10 第一三共株式会社 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート
IL297859A (en) * 2020-04-02 2023-01-01 Mersana Therapeutics Inc Antibody-drug conjugates comprising sting agonists
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
MX2022014110A (es) 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
AU2022253902A1 (en) 2021-04-10 2023-11-02 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3226976A1 (en) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
TW202342105A (zh) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024100452A2 (en) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Heterocyclic compounds as sting agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145102A1 (en) * 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
SG189811A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
MX2015006868A (es) 2012-11-30 2015-10-05 Novartis Ag Metodos para la elaboracion de conjugados a partir de proteinas que contienen disulfuro.
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
MY175308A (en) * 2013-05-18 2020-06-18 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
EP3546473A1 (en) 2014-12-16 2019-10-02 Kayla Therapeutics Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2017004499A1 (en) 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
EP4378957A2 (en) * 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
MA42608A (fr) 2015-08-13 2018-06-20 Merck Sharp & Dohme Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
JP2019521138A (ja) 2016-07-15 2019-07-25 スペロビー・バイオサイエンシズ・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145102A1 (en) * 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURENT DUCRY等: "Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592570A (zh) * 2020-05-15 2020-08-28 清华大学 新型sting激动剂及其制备方法和应用
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用

Also Published As

Publication number Publication date
AR113224A1 (es) 2020-02-19
WO2018200812A1 (en) 2018-11-01
JP2020517700A (ja) 2020-06-18
EP3615080A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
CN110799218A (zh) 包含sting激动剂的抗体缀合物
US20210346387A1 (en) Antibody conjugates comprising toll-like receptor agonist
US20200164084A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
JP2024023225A (ja) 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
CN113348181A (zh) 包含sting激动剂的dc-sign抗体缀合物
US20230053449A1 (en) Dc-sign antibody drug conjugates
BR112021011900A2 (pt) Anticorpos para pmel17 e conjugados dos mesmos
WO2020089815A1 (en) Antibody conjugates comprising sting agonist
US11701427B2 (en) Diels-alder conjugation methods
CN116096426A (zh) 用于治疗癌症的ccr7抗体药物缀合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Basel, Switzerland

Applicant after: NOVARTIS AG

Applicant after: Chinook medical Co.

Address before: Basel, Switzerland

Applicant before: NOVARTIS AG

Applicant before: ADURO BIOTECH, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200214